(lp0
S'CytRx Granted Type B Pre-NDA Meeting with US FDA for Registration Pathway with ... PR Newswire  - Jan 4, 2017 LOS ANGELES, Jan. 4, 2017 /PRNewswire/ -- CytRx Corporation , a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, today announced that,&nbsp;...'
p1
aS"CytRx to Present at the 29th Annual ROTH Conference PR Newswire  - Mar 7, 2017 LOS ANGELES, March 7, 2017 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice&nbsp;...CytRx Corporation  traded with Volume of 1.28 Million shares in ... - The Newburgh PressCytRx Corporation's  stock price is Worth at $0.42 - Hot Stocks Point"
p2
aS"Lookout for Price Target? World Fuel Services Corporation , CytRx ... StockNewsJournal - 17 hours ago CytRx Corporation , maintained return on investment for the last twelve months at -116.26, higher than what Reuters data shows regarding industry's average.CytRx Corporation  recently purchased by insider Patterson Scott Bradford - Post AnalystCytRx Corporation  Receives An Update From Brokers - The De Soto Edge"
p3
aS'CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common ... PR Newswire  - Dec 13, 2016 LOS ANGELES, Dec. 13, 2016 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into securities purchase agreements with existing&nbsp;...'
p4
aS'CytRx Corporation  Soars 5.15% on March 20 Equities.com - Mar 20, 2017 CytRx Corporation  had a good day on the market for Monday March 20 as shares jumped 5.15% to close at $0.42. About 825,181 shares traded hands on 1,703 trades for the day, compared with an average daily volume of 1.37 million shares out of a&nbsp;...CytRx Corporation  Quarterly EPS At $-0.11 - Stock ObserverCytRx Corporation  Reports Consolidated EPS Of $-0.0312 - Equities Focus'
p5
aS'CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer PR Newswire  - Dec 19, 2016 LOS ANGELES, Dec. 19, 2016 /PRNewswire/ -- CytRx Corporation , a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, has appointed Daniel&nbsp;...'
p6
aS'CYTRX CORPORATION  Files An 8-K Results of Operations and ... Market Exclusive - Mar 15, 2017 CytRx Corporation on March 15, 2017 issued a press release regarding its financial results for the year ended December 31, 2016.Stock on the Move: CytRx Corporation  - Post Registrar'
p7
aS'CytRx to Present at the 19th Annual BIO CEO &amp; Investor Conference PR Newswire  - Feb 6, 2017 LOS ANGELES, Feb. 6, 2017 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice&nbsp;...'
p8
aS'CytRx Corporation  Is A Top Contrarian Play Insider Financial - Oct 14, 2016 CytRx Corporation  has been the subject of some serious hit pieces over the last couple of months, on the back of the company announcing what was construed as disappointing results from an ongoing trial of its lead candidate,&nbsp;...'
p9
aS"CytRx: Aldoxorubicin Phase 3 Clinical Trial, Saddle Up Partner! Seeking Alpha - Jul 17, 2016 Can the retail investor survive any longer than a second line malignant cancer therapy patient in today's biotechnology market environment?"
p10
a.